中美创新药物研发监管激励政策的比较研究  

The comparative study on supervision and incentive policies of Sino-US during the innovative drug R&D

作　　者：丁锦希[1] 赵敏[1] 

机构地区：[1]中国药科大学,南京211198

出　　处：《中国新药杂志》2009年第5期387-392,共6页Chinese Journal of New Drugs

摘　　要：创新药物研发是提升我国医药产业核心竞争力的关键因素之一,其发展具有重大的社会效益和经济效益。本文就中美创新药物研发的现状进行对比,通过分析比较两国创新药物研发的监管激励政策,发现两国有关创新药物研发政策之间的差异,并在此基础上借鉴美国先进经验,探索性地提出进一步完善我国创新药研发政策的建议。Innovative drug research and development（R＆D） is one of the key factors to enhance our core competitiveness of the pharmaceutical industry,and its development is of great social and economic benefits.This article is based on the R＆D status of innovative drug in China and US to compare the control policy and incentive policies in the two countries.Understanding the policy differences and learning the advanced experience will improve China＇s drug R＆D policy.

关 键 词：创新药物研发 监管激励政策 比较研究 

分 类 号：R95[医药卫生—药学]